Viking Therapeutics (VKTX) Interest & Investment Income (2014 - 2026)

Viking Therapeutics has disclosed Interest & Investment Income across 13 years of filings, most recently posting $5.8 million for Q1 2026.

• Interest & Investment Income for Q1 2026 came in at $5.8 million, down 41.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $29.6 million (down 32.73% YoY), and the FY2025 annual result was $33.7 million, down 17.67% from the prior year.
• Interest & Investment Income came in at $5.8 million for Q1 2026 at Viking Therapeutics, down from $7.0 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $11.8 million in Q2 2024 to a low of $154000.0 in Q1 2022.
• The 5-year median for Interest & Investment Income is $5.8 million (2026), against an average of $5.7 million.
• Across the five-year window, Interest & Investment Income jumped 1697.23% in 2023 and tumbled 41.2% in 2026, its largest moves.
• Viking Therapeutics' Interest & Investment Income stood at $732000.0 in 2022, then soared by 542.9% to $4.7 million in 2023, then surged by 130.43% to $10.8 million in 2024, then tumbled by 35.13% to $7.0 million in 2025, then fell by 17.56% to $5.8 million in 2026.
• The last three Interest & Investment Income figures came in at $5.8 million (Q1 2026), $7.0 million (Q4 2025), and $7.8 million (Q3 2025), per Business Quant data.